Zelluna Immunotherapy AS
Zelluna is pioneering allogeneic ‘off-the-shelf’ T Cell Receptor-based Natural Killer (TCR-NK) cells for the treatment of solid cancers. The company’s platform combines the innate killing power of NK cells with precise solid tumour targeting of TCRs, designed to address the limitations of current cell therapies in solid tumours. The company’s lead candidate, ZI-MA4-1, is the worlds-first MAGE-A4 targeting TCR-NK therapy expected to enter clinical trials in 2026 For more info please visit www.zelluna.com
- Org.nr
- 816823862
- Bransje (NACE)
- Forskning og utviklingsarbeid innen bioteknologi
- Besøksadresse
- Ullernchausséen 64, 379.0 Oslo
- Ansatte
- 20-49
- Telefon
- 47460660
Er dette din bedrift?
Fremhev oppføringen med logo, bilder, lenke til nettsiden din og utvidet beskrivelse.
Fremhev din bedriftSist oppdatert: 22.4.2026